Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors (RIALTO)

Sanofi

Status and phase

Terminated

Phase 3

Conditions

Microalbuminuria

Obesity

Dyslipidemia

Diabetes Mellitus, Type 2

Treatments

Drug: Rimonabant

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

EudraCT # : 2006-002951-33

RIMON_L_01031

Details and patient eligibility

About

Primary objective:

To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period.

Secondary objectives:

Percentage of patients in both arms of the study whose levels of microalbuminuria decrease, stabilise, increase towards macroalbuminuria or are unchanged after 12 months of treatment with rimonabant or placebo.
To assess the effect of treatment with rimonabant 20 mg versus placebo over a 12 month period on:
- Weight and waist circumference.
- Glycaemia profile: fasting glycaemia, fasting insulinaemia and HbA1c.
- Lipid and lipoprotein profile: triglycerides, total cholesterol, HDL-C, LDL-C, apolipoproteins A1 and B.
- Inflammatory markers
- Adipocytokines.
- Blood pressure.
- Glomerular filtration rate.
To assess the quality of life by means of questionnaire filled in.
Safety parameters

Enrollment

174 patients

Sex

All

Ages

30 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Body Mass Index > 27 kg/m2 and < 40 kg/m2.
Waist circumference > 102 cm in men and > 88 cm in women.
Microalbuminuria >= 20 mg/g creatinine and < 300 mg/g creatinine in at least two of three morning urine samples taken on 3 separate days prior to the baseline visit.
Type 2 diabetes and/or dyslipidaemia.

Exclusion criteria

Breastfeeding or pregnant women or who expect to become pregnant.
Non-use of approved methods of contraception in women of child-bearing potential.
History of very low calorie diet in the 3 months prior to the screening visit (<1200 kcal/day).
Change in weight > 5 kg in the 3 months prior to the screening visit.
History of surgery for weight loss (such as vertical banded gastroplasty, gastric by-pass, etc.)
History of bulimia or anorexia nervosa according to DSM-IV definition.
Any clinically significant endocrine disorder, in the opinion of the investigator, especially known alterations in the blood concentration of TSH and free T4.
Type 1 Diabetes
Triglyceridaemia > 400 mg/dl (4.52 mmol/l)
Severe renal dysfunction
Chronic Hepatitis or clinically known significant liver disease or ALT and/or AST > 3x the upper limit of the normal range at the screening visit.
Hypertension at the screening visit.
Presence of any condition (medical, including clinically significant abnormal laboratory tests, physiological, social or geographical) actual or anticipated that the investigator feels would compromise the patient's safety or limit his/her successful participation to the study.
History of abuse of alcohol or other substances (except smoking).
Hypersensitivity or intolerance to the active ingredient or any of the excipients, such as lactose.

Concomitant medication prior to the screening visit

Administration of any treatment undergoing clinical investigation (drug or medical device) in the 30 days prior to the screening visit.
Previous treatment with rimonabant.
Administration of any of the following products in the 3 months prior to the screening visit
- Anti-obesity drugs (such as, sibutramine or orlistat).
- Other weight loss drugs (phentermine,amphetamines).
- Weight loss herbal preparations.
- Nicotinic acid, fibrates, bile acid sequestrants or Omega 3 drugs (e.g. Omacor).
- Prolonged use (more than a week) of systemic corticosteroids or neuroleptics
- Antidepressants (including bupropion)
- Insulin, thiazolidinediones, α-glucosidase inhibitors, meglitinides or any group of antidiabetic drugs (except combination of biguanides and sulfonylureas)
In type 2 diabetes patients, start of or change in treatment with sulfonylureas and/or metformin, in the 4 weeks prior to the screening visit.
Start of or change in treatment with antihypertensive drugs in the 12 weeks prior to the screening visit.
Start of or change in treatment with statins and/or ezetimibe in the 8 weeks prior to the screening visit.